The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round

Health AI startup OpenEvidence recently secured $250 million in new funding, propelling its valuation to an impressive $15 billion. Dubbed the "ChatGPT for doctors," this innovative company is revolutionizing the healthcare industry with its AI-powered search engine. OpenEvidence has quickly gained traction among medical professionals, with over two-thirds of U.S. doctors relying on its diagnostic and treatment advice.

The recent funding round saw participation from prominent hospital systems, Andreessen Horowitz, and other notable investors. OpenEvidence's valuation leap from $12 billion to $15 billion highlights the growing interest in AI-driven healthcare solutions. As the demand for AI tools in healthcare continues to surge, OpenEvidence has positioned itself as a formidable player in the market.

With relationships in place with major technology companies and significant backing from Nvidia, OpenEvidence is well-equipped to capitalize on the growing trend of AI acquisitions. Anticipating potential scarcity in compute resources due to escalating anti-AI sentiments, the company may explore M&A opportunities that provide access to essential computing power. While it remains unclear if any acquirers have shown interest, OpenEvidence may choose to remain independently operated.

Founded in 2022, OpenEvidence has experienced remarkable growth, attracting over $1 billion in funding within a year. Its AI-powered search engine has become the fastest-growing application for physicians in history, cementing its status as a trailblazer in the healthcare sector. As AI giants like OpenAI and Anthropic intensify their focus on healthcare, partnerships and acquisitions like OpenEvidence's offer a strategic advantage, providing access to a vast network of medical professionals and expertise in handling sensitive medical information.